Foster Dykema Cabot & Partners’s AbbVie ABBV Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$960K	Sell	3,815 -59	-2%	-$12.7K	0.06%	52
2026 Q1	$843K	Sell	3,874 -44	-1%	-$9.76K	0.05%	55
2025 Q4	$895K	Sell	3,918 -966	-20%	-$220K	0.06%	52
2025 Q3	$1.13M	Buy	4,884 +644	+15%	+$131K	0.07%	48
2025 Q2	$787K	Buy	4,240 +554	+15%	+$103K	0.06%	61
2025 Q1	$772K	Sell	3,686 -38	-1%	-$7.39K	0.06%	57
2024 Q4	$662K	Sell	3,724 -76	-2%	-$14K	0.05%	70
2024 Q3	$750K	Buy	3,800 +635	+20%	+$119K	0.06%	63
2024 Q2	$543K	Buy	3,165 +114	+4%	+$18.9K	0.05%	61
2024 Q1	$556K	Sell	3,051 -5	-0.2%	-$862	0.05%	61
2023 Q4	$474K	Buy	+3,056	New	+$446K	0.05%	60

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Foster Dykema Cabot & Partners's ABBV Position: Q2 2026 in Review

Foster Dykema Cabot & Partners reduced its AbbVie (ABBV) stake by 1.5% in Q2 2026, selling an estimated $12.7K and leaving 3,815 shares worth $960K. The position accounts for 0.06% of the portfolio, ranked #52.

Foster Dykema Cabot & Partners first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.13M in Q3 2025. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Foster Dykema Cabot & Partners held 3,815 shares of AbbVie worth $960K as of Q2 2026.
Foster Dykema Cabot & Partners sold 59 AbbVie shares in Q2 2026, an estimated $12.7K.
AbbVie made up 0.06% of Foster Dykema Cabot & Partners's portfolio in Q2 2026, its #52 holding.
Foster Dykema Cabot & Partners first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
Foster Dykema Cabot & Partners's AbbVie position peaked at $1.13M in Q3 2025.
4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q2 2026, filed 11 Aug 2026.